Literature DB >> 19250092

Low referral rate for prophylactic implantation of cardioverter-defibrillators in a tertiary care medical center.

Jason Bradfield1, Alberta Warner, Malcolm M Bersohn.   

Abstract

BACKGROUND: Implantable cardioverter-defibrillators (ICDs) for primary prevention became standard of care after the publication of the second Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
OBJECTIVE: To determine the percentage of patients in a Veterans Affairs medical center appropriately referred for primary prophylaxis ICD and to further categorize the reasons patients are not being referred.
METHODS: Echocardiograms obtained since the release of MADIT-II in 2002 were searched for a left ventricular ejection fraction (LVEF) < or = 35% and < or =30%. We randomly selected 120 patients per year from 2002 to 2006, for a total of 600 patients in each group. Data were reviewed to determine the number of ICD recipients and the reasons patients were not referred.
RESULTS: In the LVEF < or = 35% group an ICD was implanted in 28% of 392 eligible patients. Nonreferral (58%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 26% of cases. Overall mortality was 29% (15% with and 31% without ICD). In the LVEF < or =30% group an ICD was implanted in 33% of 388 eligible patients. Nonreferral (51%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 24% of cases. Overall mortality was 28% (18% with and 32% without ICD).
CONCLUSIONS: After the publication of MADIT-II and SCD-HeFT, only 42% of eligible patients with LVEF < or = 35% and 49% of patients with LVEF < or =30% were offered a potentially life-saving ICD between 2002 and 2006 in our medical center, sometimes with considerable delay.

Entities:  

Mesh:

Year:  2009        PMID: 19250092     DOI: 10.1111/j.1540-8159.2008.02281.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

1.  Geographic variation in implantable cardioverter-defibrillator use and heart failure survival.

Authors:  Andrew J Epstein; Daniel Polsky; Feifei Yang; Lin Yang; Peter W Groeneveld
Journal:  Med Care       Date:  2012-01       Impact factor: 2.983

2.  [Quality improvement in Germany: a way to better electrophysiology?].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-09

3.  Referring physicians' discordance with the primary prevention implantable cardioverter-defibrillator guidelines: a national survey.

Authors:  Jorge M Castellanos; Lisa M Smith; Paul D Varosy; Christine Dehlendorf; Gregory M Marcus
Journal:  Heart Rhythm       Date:  2012-02-02       Impact factor: 6.343

Review 4.  Indications for implantable cardioverter-defibrillator placement in ischemic cardiomyopathy and after myocardial infarction.

Authors:  Stavros E Mountantonakis; Mathew D Hutchinson
Journal:  Curr Heart Fail Rep       Date:  2011-12

5.  Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.

Authors:  Allen Hoang; Changyu Shen; James Zheng; Stanley Taylor; William J Groh; Marc Rosenman; Alfred E Buxton; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2014-02-22       Impact factor: 6.343

6.  A Comparative Survey of Pacemaker Implantation in Trinidad and Tobago in 2005 and 2009.

Authors:  R Henry; T Dookie; E Primus
Journal:  West Indian Med J       Date:  2014-05-15       Impact factor: 0.171

7.  Clinical and psychological impact of prophylactic implantable cardioverter-defibrillators in a community heart failure population.

Authors:  S Arnous; N F Murphy; P Pyne-Daly; Z Nawoor; D Keane; M Ledwidge; K McDonald
Journal:  Ir J Med Sci       Date:  2010-12-14       Impact factor: 1.568

8.  Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.

Authors:  Laura Lihua Chan; Choon Pin Lim; Soe Tin Aung; Paul Quetua; Kah Leng Ho; Daniel Chong; Wee Siong Teo; David Sim; Chi Keong Ching
Journal:  Singapore Med J       Date:  2016-04       Impact factor: 1.858

9.  Impact of an Automated Best Practice Alert on Sex and Race Disparities in Implantable Cardioverter-Defibrillator Therapy.

Authors:  Alvin Thalappillil; Amber Johnson; Andrew Althouse; Floyd Thoma; Jae Lee; N A Mark Estes; Sandeep Jain; Joon Lee; Samir Saba
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 6.106

10.  Factors influencing utilization of the primary prevention implantable defibrillator.

Authors:  Lin Zhang; Kumar Narayanan; Harpriya Chugh; Takahiro Shiota; Zhi-Jie Zheng; Sumeet S Chugh
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.